Thiogenesis Reports Positive Interim Phase 2 Trial Results for MELAS and Announces Pipeline Advancements in Leigh Syndrome and CystinosisTrial achieved biological proof-of-concept, dose discovery and biomarker improvementNovember 04, 2025 9:00 AM EST | Source: Thiogenesis Therapeutics, Corp.San Diego, California--(Newsfile Corp. - November 4, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing sul ...